Compound useful for the treatment of degenerative and inflammatory diseases
A novel compound able to inhibit JAK is disclosed, that comprises a compound according to Formula I: or a pharmaceutically acceptable salt thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.
1. A method for the treatment of psoriasis, comprising administering an amount of a compound according to Formula I:
or a pharmaceutically acceptable salt thereof sufficient to effect said treatment.
2. The method according to claim 1 , wherein the compound is administered in combination with one or more further therapeutic agents selected from agents for the treatment of psoriasis.
3. The method according to claim 2 , wherein the compound is administered in combination with one further therapeutic agent selected from agents for the treatment of psoriasis.
4. A method for the treatment of psoriasis, comprising administering an amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound according to Formula I:
or a pharmaceutically acceptable salt thereof, sufficient to effect said treatment.
5. A method for the treatment of psoriasis, comprising administering an amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier, a pharmaceutically effective amount of a compound according to Formula I:
or a pharmaceutically acceptable salt thereof, and a further therapeutic agent, sufficient to effect said treatment.
6. The method according to claim 4 , wherein the pharmaceutical composition is administered in combination with one or more further therapeutic agents selected from agents for the treatment of psoriasis.
7. The method according to claim 6 , wherein the pharmaceutical composition is administered in combination with one further therapeutic agent selected from agents for the treatment of psoriasis.
8. The method according to claim 5 , wherein the further therapeutic agent is an agent for the treatment of psoriasis.
9. The method according to claim 2 , wherein the further therapeutic agent is selected from topical agents selected from coal tar, dithranol, corticosteroids, vitamin D 3 analogues, and retinoids; and systemic agents selected from synthetic disease modifying, immunomodulatory agents, and biological disease modifying, immunomodulatory agents.
10. The method according to claim 3 , wherein the further therapeutic agent is selected from topical agents selected from coal tar, dithranol, corticosteroids, vitamin D 3 analogues, and retinoids; and systemic agents selected from synthetic disease modifying, immunomodulatory agents, and biological disease modifying, immunomodulatory agents.
11. The method according to claim 6 , wherein the further therapeutic agent is selected from topical agents selected from coal tar, dithranol, corticosteroids, vitamin D 3 analogues, and retinoids; and systemic agents selected from synthetic disease modifying, immunomodulatory agents, and biological disease modifying, immunomodulatory agents.
12. The method according to claim 7 , wherein the further therapeutic agent is selected from topical agents selected from coal tar, dithranol, corticosteroids, vitamin D 3 analogues, and retinoids; and systemic agents selected from synthetic disease modifying, immunomodulatory agents, and biological disease modifying, immunomodulatory agents.
13. The method according to claim 8 , wherein the further therapeutic agent is selected from topical agents selected from coal tar, dithranol, corticosteroids, vitamin D 3 analogues, and retinoids; and systemic agents selected from synthetic disease modifying, immunomodulatory agents, and biological disease modifying, immunomodulatory agents.
14. The method according to claim 9 , wherein the further therapeutic agent is selected from methotrexate, cyclosporine, retinoids, tioguanine, hydroxyurea, sulfasalazine, mycophenolate mofetil, azathioprine, tacrolimus, fumaric acid esters, and Amevive ™, Enbrel ™, Humira ™, Remicade ™, Raptiva ™ and ustekinumab.
15. The method according to claim 10 , wherein the further therapeutic agent is selected from methotrexate, cyclosporine, retinoids, tioguanine, hydroxyurea, sulfasalazine, mycophenolate mofetil, azathioprine, tacrolimus, fumaric acid esters, and Amevive ™, Enbrel ™, Humira ™, Remicade ™, Raptiva ™ and ustekinumab.
16. The method according to claim 11 , wherein the further therapeutic agent is selected from methotrexate, cyclosporine, retinoids, tioguanine, hydroxyurea, sulfasalazine, mycophenolate mofetil, azathioprine, tacrolimus, fumaric acid esters, and Amevive ™, Enbrel ™, Humira ™, Remicade ™, Raptiva ™ and ustekinumab.
17. The method according to claim 12 , wherein the further therapeutic agent is selected from methotrexate, cyclosporine, retinoids, tioguanine, hydroxyurea, sulfasalazine, mycophenolate mofetil, azathioprine, tacrolimus, fumaric acid esters, and Amevive ™, Enbrel ™, Humira ™, Remicade ™, Raptiva ™ and ustekinumab.
18. The method according to claim 13 , wherein the further therapeutic agent is selected from methotrexate, cyclosporine, retinoids, tioguanine, hydroxyurea, sulfasalazine, mycophenolate mofetil, azathioprine, tacrolimus, fumaric acid esters, and Amevive ™, Enbrel ™, Humira ™, Remicade ™, Raptiva ™ and ustekinumab.